Jacobs Levy Equity Management
PRCT icon

Jacobs Levy Equity Management’s Procept Biorobotics PRCT Stock Holding History

Jacobs Levy Equity Management’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-7,409
Closed -$262K – 1042
2023
Q2 		$262K Sell
7,409
-12,173
-62% -$402K ﹤0.01% 900
2023
Q1 		$556K Sell
19,582
-9,525
-33% -$336K ﹤0.01% 789
2022
Q4 		$1.21M Sell
29,107
-312
-1% -$13.4K 0.01% 651
2022
Q3 		$1.22M Buy
+29,419
New +$1.17M 0.01% 669

Other funds holding PRCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jacobs Levy Equity Management's PRCT Position: Q3 2023 in Review

Jacobs Levy Equity Management sold out of Procept Biorobotics (PRCT) in Q3 2023, closing a stake of 7,409 shares — an estimated $262K sold.

Jacobs Levy Equity Management first reported a position in PRCT in Q3 2022 and held it in 4 quarters. The position peaked at $1.22M in Q3 2022. 127 funds tracked by Wall St. Rank hold PRCT as of Q3 2023.

  • Jacobs Levy Equity Management reported no remaining Procept Biorobotics position as of Q3 2023 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 7,409 Procept Biorobotics shares in Q3 2023, an estimated $262K.
  • Jacobs Levy Equity Management first reported a position in Procept Biorobotics in Q3 2022 and held it in 4 quarters.
  • Jacobs Levy Equity Management's Procept Biorobotics position peaked at $1.22M in Q3 2022.
  • 127 funds tracked by Wall St. Rank held Procept Biorobotics as of Q3 2023.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2023, filed 17 Nov 2023.